Ilaria Salvi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ilaria Salvi has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Ilaria Trave
Section of Dermatology, Department of Health Sciences, University of Genoa, IRCCS, Ospedale Policlinico San Martino, Genoa, Italy
10 shared publications - Aurora Parodi
Clinica Dermatologica DissaL Ospedale Policlinico San Martino – IRCCS Genova Italy
8 shared publications Emanuele Cozzani
Clinica Dermatologica DissaL Ospedale Policlinico San Martino – IRCCS Genova Italy
8 shared publications- Emanuele Cozzani
Department of Health Sciences, University of Genoa, Genoa, Italy
5 shared publications Aurora Parodi
4 shared publications- Martina Burlando
Section of Dermatology, Department of Health Sciences (DISSAL), University of Genoa, 16132 Genova, Italy
4 shared publications
Latest Publications
- 7 August 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (5) , 498-500
Occupational Hand Eczema and Contact Sensitization Among Dental Healthcare Students in an Italian University Center
- 7 August 2026
- Published by Wiley in Contact Dermatitis
- Vol. 95 (5) , 498-500
Occupational Hand Eczema and Contact Sensitization Among Dental Healthcare Students in an Italian University Center
- Open Access
- 29 June 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Two Painful Occipital Nodules in a Child Returning from South America: A Quiz
- 29 June 2026
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 106
Open AccessTwo Painful Occipital Nodules in a Child Returning from South America: A Quiz
- Open Access
- 5 May 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (5) , 628-633
Unterschiedliche anatomische Spezifitäten des residualen PASI bei Biologikatherapien der Psoriasis
Zusammenfassung: Hintergrund und Ziele: Ein besseres Verständnis der Immunpathogenese der Psoriasis hat zur Entwicklung effektiver zielgerichteter Therapien geführt. Allerdings weisen Patienten, die ohne vollständige Abheilung auf die Behandlung ansprechen, eine Resterkrankung auf. Das Ziel dieser Studie war es, spezifische anatomische Lokalisationen der residualen Erkrankung (oder des residualen Psoriasis Area Severity Index [PASI]) in Bezug auf verschiedene Biologika nachzuweisen. Methoden und Patienten: In dieser retrospektiven, multizentrischen Beobachtungsstudie wurden die klinischen Daten von Patienten mit Psoriasis analysiert, die mindestens 6 Monate lang mit Biologika behandelt worden waren. Die Datenanalyse konzentrierte sich auf Patienten mit residualem PASI. Ergebnisse: Insgesamt 228 von 1.000 Patienten wiesen trotz Erreichen eines PASI 90 in den Wochen 24 bis 28 der Biologikatherapie eine Resterkrankung auf. Die am häufigsten von der residualen Erkrankung betroffenen anatomischen Lokalisationen waren die unteren Extremitäten (44,3%). Wir beobachteten Unterschiede zwischen den Biologika hinsichtlich der Häufigkeit und Lokalisation der Erkrankung. Die Lokalisation residualer Hautläsionen an den Beinen stand im Zusammenhang mit einem Wechsel oder einer Unterbrechung der Behandlung. Die Wirkstoffe mit dem höchsten beziehungsweise niedrigsten Anteil an Patienten mit residualer Erkrankung an den unteren Extremitäten waren Secukinumab und Risankizumab. Schlussfolgerungen: Die Behandlung mit Anti‐IL‐17‐ und Anti‐IL‐23‐Medikamenten ist durch die Persistenz residualer Läsionen gekennzeichnet, wobei Unterschiede hinsichtlich der Häufigkeit und der anatomischen Lokalisationen bestehen.
- 5 May 2026
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (5) , 628-633
Open AccessUnterschiedliche anatomische Spezifitäten des residualen PASI bei Biologikatherapien der Psoriasis
Zusammenfassung: Hintergrund und Ziele: Ein besseres Verständnis der Immunpathogenese der Psoriasis hat zur Entwicklung effektiver zielgerichteter Therapien geführt. Allerdings weisen Patienten, die ohne vollständige Abheilung auf die Behandlung ansprechen, eine Resterkrankung auf. Das Ziel dieser Studie war es, spezifische anatomische Lokalisationen der residualen Erkrankung (oder des residualen Psoriasis Area Severity Index [PASI]) in Bezug auf verschiedene Biologika nachzuweisen. Methoden und Patienten: In dieser retrospektiven, multizentrischen Beobachtungsstudie wurden die klinischen Daten von Patienten mit Psoriasis analysiert, die mindestens 6 Monate lang mit Biologika behandelt worden waren. Die Datenanalyse konzentrierte sich auf Patienten mit residualem PASI. Ergebnisse: Insgesamt 228 von 1.000 Patienten wiesen trotz Erreichen eines PASI 90 in den Wochen 24 bis 28 der Biologikatherapie eine Resterkrankung auf. Die am häufigsten von der residualen Erkrankung betroffenen anatomischen Lokalisationen waren die unteren Extremitäten (44,3%). Wir beobachteten Unterschiede zwischen den Biologika hinsichtlich der Häufigkeit und Lokalisation der Erkrankung. Die Lokalisation residualer Hautläsionen an den Beinen stand im Zusammenhang mit einem Wechsel oder einer Unterbrechung der Behandlung. Die Wirkstoffe mit dem höchsten beziehungsweise niedrigsten Anteil an Patienten mit residualer Erkrankung an den unteren Extremitäten waren Secukinumab und Risankizumab. Schlussfolgerungen: Die Behandlung mit Anti‐IL‐17‐ und Anti‐IL‐23‐Medikamenten ist durch die Persistenz residualer Läsionen gekennzeichnet, wobei Unterschiede hinsichtlich der Häufigkeit und der anatomischen Lokalisationen bestehen.
- Open Access
- 20 March 2026
- Published by PAGEPress Publications in Dermatology Reports
Does the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?
According to the Italian Medicines Agency (AIFA) guidelines, patients with moderate-to-severe psoriasis can access biological therapies in case of treatment failure or contraindication to at least one conventional systemic treatment. However, no studies have been conducted to investigate the potential influence of previous conventional systemic treatments on the efficacy of subsequently prescribed biologics. The purpose of this study was to evaluate whether patients treated with bimekizumab, a monoclonal anti-interleukin (IL)-17A/F drug, achieve Psoriasis Area and Severity Index (PASI) 90 at different times based on prior use of cyclosporine or methotrexate. Fifty-four patients were enrolled in this study; 29 had previously been treated with methotrexate and 25 with cyclosporine. There was a statistically significant difference in efficacy (measured by mean PASI score) at week 4 (p<0.01), with patients treated with methotrexate responding faster to bimekizumab. Females previously on treatment with cyclosporine responded better and faster, followed by females on methotrexate and then men on methotrexate. Men on cyclosporine showed a later response to bimekizumab. Our study confirmed that bimekizumab is a fast and effective biologic treatment for psoriasis. Patients previously treated with methotrexate responded faster to bimekizumab than those formerly treated with cyclosporine.
- 20 March 2026
- Published by PAGEPress Publications in Dermatology Reports
Open AccessDoes the response to bimekizumab vary according to previous therapy with methotrexate versus cyclosporine?
According to the Italian Medicines Agency (AIFA) guidelines, patients with moderate-to-severe psoriasis can access biological therapies in case of treatment failure or contraindication to at least one conventional systemic treatment. However, no studies have been conducted to investigate the potential influence of previous conventional systemic treatments on the efficacy of subsequently prescribed biologics. The purpose of this study was to evaluate whether patients treated with bimekizumab, a monoclonal anti-interleukin (IL)-17A/F drug, achieve Psoriasis Area and Severity Index (PASI) 90 at different times based on prior use of cyclosporine or methotrexate. Fifty-four patients were enrolled in this study; 29 had previously been treated with methotrexate and 25 with cyclosporine. There was a statistically significant difference in efficacy (measured by mean PASI score) at week 4 (p<0.01), with patients treated with methotrexate responding faster to bimekizumab. Females previously on treatment with cyclosporine responded better and faster, followed by females on methotrexate and then men on methotrexate. Men on cyclosporine showed a later response to bimekizumab. Our study confirmed that bimekizumab is a fast and effective biologic treatment for psoriasis. Patients previously treated with methotrexate responded faster to bimekizumab than those formerly treated with cyclosporine.
- Open Access
- 19 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Risk of Relapse Upon Treatment Discontinuation in Rosacea: An Updated Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials
Background: Rosacea treatments often lead to recurrence after discontinuation, highlighting the need for effective maintenance therapies. The long‐term efficacy of treatments in preventing relapse has not been systematically compared. Objectives: To compare the risk of relapse upon treatment discontinuation after achieving clinical remission with both topical and systemic therapies. Methods: Updated systematic review and network meta‐analysis of randomized controlled studies following PRISMA guidelines. A thorough literature search across different databases to identify randomized controlled trials (RCTs) on treatment relapse rates in adult patients with moderate to severe papulopustular rosacea treated with systemic and topical treatments was conducted. Data were independently extracted, and the risk of bias was assessed using the Cochrane tool. Statistical analyses were performed using network meta‐analysis with random effects models. Results: A total of seven out of an initial 14,450 articles screened were retrieved, involving 632 patients with moderate to severe rosacea and 552 controls treated with metronidazole 0.75% gel, doxycycline 40 mg, ivermectin 1% cream, isotretinoin 0.25 mg/kg/day, hydroxychloroquine 200 mg, and aminolevulinic acid photodynamic therapy. Results showed that isotretinoin and metronidazole significantly prevented rosacea relapse compared to placebo, with isotretinoin ranked as the most effective treatment according to SUCRA rankings. The average time regarding relapse varied among studies, with metronidazole showing a shorter relapse period (12 weeks) than ivermectin (21 weeks). The risk of bias was low, with no significant publication bias detected. The limits of this review were the relatively small number of studies included and the high degree of indirectness that was noted across these studies, potentially affecting the reliability of some estimates. Conclusion: Rosacea remission can be maintained for a certain period of time after the discontinuation of the treatment and also during the treatments. Isotretinoin might be effective in reducing the risk of relapse.
- 19 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1)
Open AccessRisk of Relapse Upon Treatment Discontinuation in Rosacea: An Updated Systematic Review and Network Meta‐Analysis of Randomized Controlled Trials
Background: Rosacea treatments often lead to recurrence after discontinuation, highlighting the need for effective maintenance therapies. The long‐term efficacy of treatments in preventing relapse has not been systematically compared. Objectives: To compare the risk of relapse upon treatment discontinuation after achieving clinical remission with both topical and systemic therapies. Methods: Updated systematic review and network meta‐analysis of randomized controlled studies following PRISMA guidelines. A thorough literature search across different databases to identify randomized controlled trials (RCTs) on treatment relapse rates in adult patients with moderate to severe papulopustular rosacea treated with systemic and topical treatments was conducted. Data were independently extracted, and the risk of bias was assessed using the Cochrane tool. Statistical analyses were performed using network meta‐analysis with random effects models. Results: A total of seven out of an initial 14,450 articles screened were retrieved, involving 632 patients with moderate to severe rosacea and 552 controls treated with metronidazole 0.75% gel, doxycycline 40 mg, ivermectin 1% cream, isotretinoin 0.25 mg/kg/day, hydroxychloroquine 200 mg, and aminolevulinic acid photodynamic therapy. Results showed that isotretinoin and metronidazole significantly prevented rosacea relapse compared to placebo, with isotretinoin ranked as the most effective treatment according to SUCRA rankings. The average time regarding relapse varied among studies, with metronidazole showing a shorter relapse period (12 weeks) than ivermectin (21 weeks). The risk of bias was low, with no significant publication bias detected. The limits of this review were the relatively small number of studies included and the high degree of indirectness that was noted across these studies, potentially affecting the reliability of some estimates. Conclusion: Rosacea remission can be maintained for a certain period of time after the discontinuation of the treatment and also during the treatments. Isotretinoin might be effective in reducing the risk of relapse.
- Open Access
- 11 October 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (5) , 628-632
Biologic treatments for psoriasis have different anatomical specificities in residual PASI
Summary: Background and objectives: Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI) anatomical localizations related to different biologic agents. Methods and patients: This retrospective, observational, multi‐center study analyzed clinical data of patients affected by psoriasis who had received biologic treatments for at least 6 months. The data analysis focused on patients with residual PASI. Results: A total of 228 of 1,000 patients showed residual disease despite achieving PASI 90 at weeks 24–28 of biologic treatment. The anatomical sites most frequently involved in residual disease were the lower limbs (44.3%). We observed differences among the biologic agents in terms of frequency and localization of residual disease. The localization of residual skin lesions to lower limbs was associated with treatment switching/interruption. The drugs with the highest and lowest proportion of patients with residual disease in the lower limbs were, respectively, secukinumab and risankizumab. Conclusions: Treatment with anti‐IL‐17 and anti‐IL‐23 drugs is characterized by the persistence of residual skin lesions with differences in terms of frequency and anatomical localizations.
- 11 October 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 24 (5) , 628-632
Open AccessBiologic treatments for psoriasis have different anatomical specificities in residual PASI
Summary: Background and objectives: Improved understanding of the immunopathogenesis of psoriasis has led to the development of effective targeted therapies, but patients who respond to treatment without total skin clearance have residual disease. The aim of this study was to demonstrate the existence of specific residual disease (or residual PASI) anatomical localizations related to different biologic agents. Methods and patients: This retrospective, observational, multi‐center study analyzed clinical data of patients affected by psoriasis who had received biologic treatments for at least 6 months. The data analysis focused on patients with residual PASI. Results: A total of 228 of 1,000 patients showed residual disease despite achieving PASI 90 at weeks 24–28 of biologic treatment. The anatomical sites most frequently involved in residual disease were the lower limbs (44.3%). We observed differences among the biologic agents in terms of frequency and localization of residual disease. The localization of residual skin lesions to lower limbs was associated with treatment switching/interruption. The drugs with the highest and lowest proportion of patients with residual disease in the lower limbs were, respectively, secukinumab and risankizumab. Conclusions: Treatment with anti‐IL‐17 and anti‐IL‐23 drugs is characterized by the persistence of residual skin lesions with differences in terms of frequency and anatomical localizations.
- Open Access
- 31 July 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (3) , 5401
Clinical, Dermoscopic, and Histopathological Features of Spitzoid Lesions in Adult Patients: Insights from a Retrospective Study
Introduction: Spitzoid lesions are a group of melanocytic tumors, including Spitz nevi, atypical Spitz tumors and Spitz melanomas, that pose a considerable diagnostic challenge. Objectives: Our aim was to describe the clinical, dermoscopic, and histopathological characteristics of spitzoid melanocytic lesions in adult patients in our center and to find possible associations between certain clinico-dermoscopic characteristics and the diagnosis of melanoma. Methods: We conducted a single-center retrospective study and included all cases of histopathological confirmed spitzoid melanocytic lesions diagnosed in adult patients between January 2012 and December 2022. We collected patient demographic characteristics and clinical, dermoscopic, and histopathological characteristics of the studied lesions. Results: Histopathological examinations of the 103 lesions included in the study revealed 4 Spitz melanomas (3.9%) and 99 non-melanomas, of which 92 were Spitz nevi (89.3%) and 7 atypical Spitz tumors (6.8%). The association between lower limb localization and diagnosis of melanoma was statistically significant (4/4 vs 45/99 patients, p=0.048). A statistically significant association between raised and pigmented morphology and malignant histology was found (4/4 vs 37/99 lesions, p=0.0229). Dermoscopy revealed that a multicomponent pattern was significantly associated with a diagnosis of melanoma (100% vs 21.6%, p<0.01) and a vascular pattern was significantly associated with atypical Spitz tumors (80% vs 28.8%, p=0.0343). Conclusions: In our cohort, some clinical characteristics (lower limb location, greater dimension, pigmentation and palpability) and dermoscopic patterns (multicomponent) were associated with a diagnosis of melanoma. Dermatologists should be careful whenever they encounter any spitzoid-looking lesions in adults, especially in case of older patients.
- 31 July 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (3) , 5401
Open AccessClinical, Dermoscopic, and Histopathological Features of Spitzoid Lesions in Adult Patients: Insights from a Retrospective Study
Introduction: Spitzoid lesions are a group of melanocytic tumors, including Spitz nevi, atypical Spitz tumors and Spitz melanomas, that pose a considerable diagnostic challenge. Objectives: Our aim was to describe the clinical, dermoscopic, and histopathological characteristics of spitzoid melanocytic lesions in adult patients in our center and to find possible associations between certain clinico-dermoscopic characteristics and the diagnosis of melanoma. Methods: We conducted a single-center retrospective study and included all cases of histopathological confirmed spitzoid melanocytic lesions diagnosed in adult patients between January 2012 and December 2022. We collected patient demographic characteristics and clinical, dermoscopic, and histopathological characteristics of the studied lesions. Results: Histopathological examinations of the 103 lesions included in the study revealed 4 Spitz melanomas (3.9%) and 99 non-melanomas, of which 92 were Spitz nevi (89.3%) and 7 atypical Spitz tumors (6.8%). The association between lower limb localization and diagnosis of melanoma was statistically significant (4/4 vs 45/99 patients, p=0.048). A statistically significant association between raised and pigmented morphology and malignant histology was found (4/4 vs 37/99 lesions, p=0.0229). Dermoscopy revealed that a multicomponent pattern was significantly associated with a diagnosis of melanoma (100% vs 21.6%, p<0.01) and a vascular pattern was significantly associated with atypical Spitz tumors (80% vs 28.8%, p=0.0343). Conclusions: In our cohort, some clinical characteristics (lower limb location, greater dimension, pigmentation and palpability) and dermoscopic patterns (multicomponent) were associated with a diagnosis of melanoma. Dermatologists should be careful whenever they encounter any spitzoid-looking lesions in adults, especially in case of older patients.
- Open Access
- 29 April 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2495831
Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab
Dupilumab, an interleukin 4 (IL-4) receptor α-antagonist approved for the treatment of atopic dermatitis, is considered effective in preventing disease recurrences. However, the incidence and characteristics od atopic dermatitis flares during treatment with dupilumab in a real-life setting have not been described in the literature. This study aims to evaluate the prevalence of disease flares in patients in treatment with dupilumab and to describe the features of flares in our study population. We conducted a retrospective observational study in which we collected demographic and clinical data on adult patients with a diagnosis of severe atopic dermatitis in treatment with dupilumab for a minimum of six months, who reached EASI75 within six months of treatment initiation. Ninety-nine patients were enrolled. Recurrences were recorded for 38.4% of patients and 7.1% developed a second recurrence. The EASI at recurrence was always lower than the EASI before treatment initiation. The localization of disease at head and neck before treatment was associated to the same localization of disease at the first recurrence (p = 0.011). The risk of recurrence was associated to the baseline EASI score (p = 0.005). The presence of dupilumab-related conjunctivitis was significantly associated to recurrences (p = 0.02). Treatment with dupilumab does not exclude the risk of a relapse, which can be estimated around 50% within a timespan of three years. In the most cases, flares should not be regarded as treatment failures, and can be easily managed with additional treatment.
- 29 April 2025
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2495831
Open AccessFrequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab
Dupilumab, an interleukin 4 (IL-4) receptor α-antagonist approved for the treatment of atopic dermatitis, is considered effective in preventing disease recurrences. However, the incidence and characteristics od atopic dermatitis flares during treatment with dupilumab in a real-life setting have not been described in the literature. This study aims to evaluate the prevalence of disease flares in patients in treatment with dupilumab and to describe the features of flares in our study population. We conducted a retrospective observational study in which we collected demographic and clinical data on adult patients with a diagnosis of severe atopic dermatitis in treatment with dupilumab for a minimum of six months, who reached EASI75 within six months of treatment initiation. Ninety-nine patients were enrolled. Recurrences were recorded for 38.4% of patients and 7.1% developed a second recurrence. The EASI at recurrence was always lower than the EASI before treatment initiation. The localization of disease at head and neck before treatment was associated to the same localization of disease at the first recurrence (p = 0.011). The risk of recurrence was associated to the baseline EASI score (p = 0.005). The presence of dupilumab-related conjunctivitis was significantly associated to recurrences (p = 0.02). Treatment with dupilumab does not exclude the risk of a relapse, which can be estimated around 50% within a timespan of three years. In the most cases, flares should not be regarded as treatment failures, and can be easily managed with additional treatment.
- Open Access
- 29 January 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (1) , 4629
Stevens-Johnson Syndrome and Erythema Multiforme Induced by Imiquimod 5% Cream
Introduction: Topical imiquimod is a safe and effective treatment for actinic keratoses, superficial basal cell carcinomas and anogenital warts. The treatment is commonly associated with local inflammatory reactions, while systemic side effects are rare and generally mild. Only few cases of erythema multiforme and Stevens-Johnson syndrome have been described in association with topical imiquimod application. Objective: We present a review of the existing cases of erythema multiforme and Stevens-Johnson syndrome reported in the literature, analyzing the clinical appearance, the histology and the treatment of the lesions. Method: Nine case of erythema multiforme were reported, characterized by cutaneous rash, bullae, crusting, erosive and targetoid lesions, mainly located at the extremities. Mucosal involvement and systemic symptoms were sometimes present. Results: Three cases of Stevens-Johnson syndrome were associated with topical imiquimod. In all cases, the authors reported targetoid lesions and areas of erosion affecting trunk and limbs, associated with systemic symptoms, and, in 2 cases, to mucosal erosions. Conclusions: We hypothesize a possible role of interferon-γ, a cytokine involved in the pathogenesis of both herpes-associated erythema multiforme and Stevens-Johnson syndrome, which is released in response to the administration of imiquimod.
- 29 January 2025
- Published by Mattioli1885 in Dermatology Practical & Conceptual
- Vol. 15 (1) , 4629
Open AccessStevens-Johnson Syndrome and Erythema Multiforme Induced by Imiquimod 5% Cream
Introduction: Topical imiquimod is a safe and effective treatment for actinic keratoses, superficial basal cell carcinomas and anogenital warts. The treatment is commonly associated with local inflammatory reactions, while systemic side effects are rare and generally mild. Only few cases of erythema multiforme and Stevens-Johnson syndrome have been described in association with topical imiquimod application. Objective: We present a review of the existing cases of erythema multiforme and Stevens-Johnson syndrome reported in the literature, analyzing the clinical appearance, the histology and the treatment of the lesions. Method: Nine case of erythema multiforme were reported, characterized by cutaneous rash, bullae, crusting, erosive and targetoid lesions, mainly located at the extremities. Mucosal involvement and systemic symptoms were sometimes present. Results: Three cases of Stevens-Johnson syndrome were associated with topical imiquimod. In all cases, the authors reported targetoid lesions and areas of erosion affecting trunk and limbs, associated with systemic symptoms, and, in 2 cases, to mucosal erosions. Conclusions: We hypothesize a possible role of interferon-γ, a cytokine involved in the pathogenesis of both herpes-associated erythema multiforme and Stevens-Johnson syndrome, which is released in response to the administration of imiquimod.
- Open Access
- 27 August 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (9) , 2645-2652
A 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice
Introduction The efficacy and safety of tildrakizumab for the treatment of plaque psoriasis were demonstrated by randomized clinical studies, but the reappraisal of prolonged experiences in the clinical practice helps to optimize the use of this biologic drug. The aim of this study was to evaluate the long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the real world. Methods This is a long-term retrospective observational study in a real-life setting. Overall, 136 adult patients with moderate-to-severe plaque psoriasis and treated with tildrakizumab were included. Results One hundred percent reduction of Psoriasis Area Severity Index (PASI100) was reached by 21.7% of patients at 4 weeks of therapy and by 51.2% at week 16, and the proportion of patients with this improvement was between 66.9% and 64.5% from 36 weeks to 3 years. The mean PASI of the cohort progressively improved from 12.6 at baseline to 1.8 at week 36 and was stable at 1 year, 2 years and 3 years. We could not confirm a previous observation that patients naïve to biologic had a better response, but we observed that those with a short history of psoriasis had a higher probability of 90% PASI reduction (PASI90) or PASI 100 within 36 weeks, suggesting that early treatment could be useful. Conclusion This long-term observation in the real life of patients with moderate-to-severe plaque psoriasis receiving tildrakizumab 100 mg showed that PASI100 can be obtained in a high proportion of patients by week 36 and be maintained for up to 3 years.
- 27 August 2024
- Published by Springer Nature in Dermatology and Therapy
- Vol. 14 (9) , 2645-2652
Open AccessA 3-Year Experience with Tildrakizumab Treatment for Patients with Plaque Psoriasis in Clinical Practice
Introduction The efficacy and safety of tildrakizumab for the treatment of plaque psoriasis were demonstrated by randomized clinical studies, but the reappraisal of prolonged experiences in the clinical practice helps to optimize the use of this biologic drug. The aim of this study was to evaluate the long-term efficacy of tildrakizumab in patients with moderate-to-severe psoriasis in the real world. Methods This is a long-term retrospective observational study in a real-life setting. Overall, 136 adult patients with moderate-to-severe plaque psoriasis and treated with tildrakizumab were included. Results One hundred percent reduction of Psoriasis Area Severity Index (PASI100) was reached by 21.7% of patients at 4 weeks of therapy and by 51.2% at week 16, and the proportion of patients with this improvement was between 66.9% and 64.5% from 36 weeks to 3 years. The mean PASI of the cohort progressively improved from 12.6 at baseline to 1.8 at week 36 and was stable at 1 year, 2 years and 3 years. We could not confirm a previous observation that patients naïve to biologic had a better response, but we observed that those with a short history of psoriasis had a higher probability of 90% PASI reduction (PASI90) or PASI 100 within 36 weeks, suggesting that early treatment could be useful. Conclusion This long-term observation in the real life of patients with moderate-to-severe plaque psoriasis receiving tildrakizumab 100 mg showed that PASI100 can be obtained in a high proportion of patients by week 36 and be maintained for up to 3 years.